Sunday , November 28 2021

A new treatment can kill cancerous tumors in the neck and head in patients with terminal illnesses. The experience of a 77-year-old patient



[ad_1]

In one study, a cocktail of immunotherapy drugs used patients ’immune systems to kill cancer cells and increase survival, researchers at the Cancer Research Institute (ICR) in London and Royal said. Marsden NHS Foundation Trust.

Barry Ambrose, a 77-year-old study participant, was diagnosed with neck cancer in 2017 and was told it had already spread to his lungs and that palliative care at the hospital was his only option. He told The Guardian that he did not hesitate to join the studio:

“When I was informed about the study … I didn’t hesitate to join. What did I have to lose? It turned out to be an opportunity to save. Although I had to go twice a week from Suffolk to the hospital to receive treatment, had no side effects and I was able to continue my life and do the things I enjoy: surfing, cycling and spending time with my family, ”said the patient.

About eight weeks after starting treatment, tests showed that the throat tumor had been destroyed.

“When the nurses called me to tell me that after two months the tumor in my throat had completely disappeared, it was an amazing moment,” Ambrose said. “Even though there were still lung diseases at the time, the effect was amazing.”

The new treatment has fewer side effects than chemotherapy

According to experts, the combination of treatments with nivolumab and ipilimumab is a new effective weapon against various forms of cancer.

In addition to increasing patients ’chances of long-term survival, the scientists said that immunotherapy treatment also triggered far fewer side effects compared to chemotherapy, a standard treatment offered to advanced patients.

The results of the phase 3 study, which involved about 1,000 patients with dying head and neck tumors, were early and not statistically significant, but were “clinically significant,” researchers said. ICR.

If you like this article, we hope you join the community of readers on our Facebook page, with a Like below:

[ad_2]
Source link